Y-mAbs Therapeutics

November 27, 2020

Danyelza validates a flotation and an anticancer mechanism

October 30, 2020

Go or no go? Big decisions loom for Bristol and Sanofi

The FDA will have a busy November, with decisions due for Bristol, Sanofi and Y-mabs, among others.

December 10, 2018

Macrogenics’ safety scare could be contagious

It could be hard for Macrogenics to shake off new safety concerns, whether it is the DART bispecific construct or its protein target that is to blame.

Y-mAbs Therapeutics

Danyelza validates a flotation and an anticancer mechanism

Go or no go? Big decisions loom for Bristol and Sanofi

Macrogenics’ safety scare could be contagious

Latest Reports

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

Evaluate Vantage COVID-19 Report

Editor's Picks

Pfizer and Biontech snatch first Covid vaccine victory

Scanning the horizon for future Covid-19 treatments

Ash 2020 preview – early winners and losers

Biogen’s aducanumab heads for US approval

Balancing the accuracy and cost of antigen testing